Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485303 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
A Phase 2 study, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00485303 is a Phase 2 study that has completed, run by Cougar Biotechnology. The registered enrollment target is 58 participants.
The verdict
NCT00485303, a Phase 2 study, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
Interventions
- DRUG Prednisone
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00485303
The ClinicalTrials.gov registry entry for NCT00485303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT00485303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00485303 about?
NCT00485303 is a clinical study titled "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy". The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
What is the current status of trial NCT00485303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2007-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00485303?
The interventions under investigation include: Prednisone (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT00485303?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.